Takeda
Evotec, Takeda Pharmaceuticals Partner on RNA-Targeting Drug Development
The companies will work together to identify and develop small molecule drugs against RNA targets that fit within Takeda's disease areas of focus.
UK Biobank Collaborating With Biopharmas to Profile Plasma Proteome of 53K Subjects
Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.
Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Twist Bioscience, Takeda Pharma Partner to Develop Antibodies for Oncology, Rare Diseases
Twist will give Takeda access to its phage display libraries to help Takeda discover and validate antibodie
Takeda's Alunbrig Gets First-Line FDA Approval With Abbott CDx in ALK-Positive Lung Cancer
The approval was based on data showing superior efficacy for Alunbrig compared to Pfizer's Xalkori, especially in patients with brain metastasis.
Aug 15, 2019
Apr 16, 2014
Jun 19, 2013